News - Eli Lilly

Filter

Current filters:

Eli Lilly

Popular Filters

50 to 74 of 205 results

Eli Lilly latest to become embroiled in China bribery allegations

23-08-2013

In the ongoing allegations of bribery and corruption by multinational drugmakers in China, US pharma…

Asia-PacificEli LillyLegalMarkets & MarketingPharmaceutical

NICE holds second consultation on Alimta for lung cancer maintenance

20-08-2013

The UK's drugs watchdog the National Institute of Health and Care Excellence (NICE) is holding a second…

AlimtaEli LillyEuropeOncologyPharmaceuticalRegulation

Positive Ph III data for Trajenta in elderly type 2 diabetes patients

15-08-2013

Elderly people with type 2 diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4)…

Boehringer IngelheimDiabetesEli LillyPharmaceuticalResearchTradjentaTrajenta

Eli Lilly's investigational sNSCLC drug meets Ph III endpoint

14-08-2013

US drug major Eli Lilly's (NYSE: LLY) shares rose nearly 4% to $56.21in pre-market trading when the company…

BiotechnologyBristol-Myers SquibbEli LillynecitumumabOncologyPharmaceuticalResearch

Drug developed by UCSF researcher continues to show promise in type 1 diabetes

11-08-2013

Teplizumab, an experimental drug designed to block the advance of type 1 diabetes in its earliest stages…

DiabetesEli LillyPharmaceuticalResearchteplizumab

TVM Life Science Ventures invests in Ixchelsis

09-08-2013

Canada-based TVM Life Science Ventures VII has announced the fund's second investment, with Ixchelsis…

Eli LillyFinancialIX-01IxchelsisMen's HealthPfizerPharmaceuticalResearch

Boehringer Ingelheim and Eli Lilly launch linagliptin trial

01-08-2013

German family-owned drug major Boehringer Ingelheim and US pharma major Eli Lilly (NYSE: LLY) have enrolled…

Boehringer IngelheimDiabetesEli LillyEuropelinagliptinPharmaceuticalResearch

Adocia re-acquires exclusive rights to insulin analog from US drug major

30-07-2013

French biotech firm Adocia (Euronext Paris: ADOC) has agreed with US pharma major Eli Lilly (NYSE: LLY)…

AdociaBiotechnologyDiabetesEli LillyLicensingPharmaceutical

Transition in new licensing deal with Eli Lilly

24-07-2013

Canada's Transition Therapeutics (TSX: TTH) has entered an exclusive licensing of worldwide rights to…

Anti-Arthritics/RheumaticsEli LillyLicensingPharmaceuticalTransition TherapeuticsTT-601

Eli Lilly records higher than expected earnings in 2nd-qtr results

24-07-2013

US drug major Eli Lilly's (NYSE: LLY) recorded higher than expected earnings as growth in key products…

AlimtaCialisCymbaltaEffientEli LillyEvistaFinancialForteoHumalogNorth AmericaPharmaceuticalStratteraZyprexa

US and European Rxing decisions on metastatic colorectal cancer

15-07-2013

The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

AvastinBayerEli LillyEuropeMarkets & MarketingNorth AmericaOncologyPharmaceuticalramucirumabRegeneronRocheSanofiStivargaZaltrap

Daiichi Sankyo's anti-clotting drug shows promise in Ph III CAD study

14-07-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) presented positive results of the PRASFIT-Elective Phase…

Cardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelResearch

Lilly's Lechleiter back in the driving seat following aorta surgery

09-07-2013

John Lechleiter has returned to his duties as chairman, president, and chief executive of US drug major…

Eli LillyManagementPharmaceutical

Lilly and Boehringer Ingelheim's basal insulin MAA accepted by EMA

08-07-2013

US drug major Eli Lilly (NYSE: LLY) and family-owned German pharma firm Boehringer Ingelheim today (July…

Boehringer IngelheimDiabetesEli LillyLantusNovo NordiskPharmaceuticalSanofiVictoza

Rise of rheumatoid arthritis therapies: JAK inhibitor battle and biosimilar threats

26-06-2013

An approval of US drug major Eli Lilly (NYSE: LLY) and Incyte Pharmaceuticals'(Nasdaq: INCY) drug baricitinib…

Anti-Arthritics/RheumaticsbaricitinibBiotechnologyEli LillyIncyteMarkets & MarketingPfizerPharmaceuticalPricingXeljanz

More ADA highlights, from Eli Lilly on dulaglutide, J&J on Invokana and GSK on albiglutide

24-06-2013

Continued news from the 73rd Scientific Sessions of the American Diabetes Association being held in Chicago,…

albiglutideDiabetesdulaglutideEli LillyGlaxoSmithKlineInvokanaJohnson & JohnsonLY605541PharmaceuticalResearch

FDA approves Boehringer and Lilly's Tradjenta and Jentadueto labeling to reflect pancreatitis risk

21-06-2013

German family-owned Boehringer Ingelheim and US partner Eli Lilly (NYSE: LLY) revealed yesterday (June…

Boehringer IngelheimDiabetesEli LillyJentaduetoNorth AmericaPharmaceuticalRegulationTradjenta

FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv

19-06-2013

The US Food and Drug Administration yesterday (June 18) revealed it is investigating two unexplained…

Eli LillyNeurologicalNorth AmericaPharmaceuticalRegulationZyprexa

Daiichi Sankyo files for Japanese approval of Prasugrel

18-06-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) says that it has submitted a New Drug Application to the…

Asia-PacificCardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelRegulation

50 to 74 of 205 results

Back to top